| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Institute of Immunology and Transfusion Medicine (Drs. Wandinger, Jabs, Kirchner, and Hennig, and A. Siekhaus), and the Departments of Neurology (Drs. Bubel, Trillenberg, and Wessel) and Pediatrics (Dr. Wagner), University of Lübeck School of Medicine, Germany.
Address correspondence and reprint requests to Dr. Klaus-Peter Wandinger, c/o Dr. F. Zipp, Department of Neurology, Charité Campus Mitte, Schumannstrasse 20/21, 10098 Berlin, Germany.
OBJECTIVE: To assess the potential significance of Epstein–Barr virus (EBV) reactivation in disease activity in MS patients.
METHODS: The prevalence of antibodies against herpes simplex virus type 1 (HSV-1), HSV-2, EBV, and cytomegalovirus was determined in a group of 108 MS patients and in 163 healthy control subjects. Sera were analyzed using combinations of novel assay systems employing highly purified viral and recombinant antigens. In addition, PCR for the detection of EBV DNA was performed in serial samples.
RESULTS: In contrast to the control populations, antibodies against EBV were present in 100% of MS patients. Among the tested human herpesviruses, this high extent of seropositivity was only found for EBV. Primary infection was found exclusively in the control group (3.7%), whereas serologic evidence of EBV reactivation was seen in MS patients (13.9%) as well as control subjects (17.2%). There was no temporal coincidence between EBV reactivation and disease activity in MS patients. However, in 19 patients followed monthly for 1 year, active viral replication as measured by increased immunoglobulin (Ig) M and IgA responses to EBV early antigens (p54 + p138) and positive serum DNA was seen in 72.7% of patients with exacerbations during the study period and in none of the patients with clinically stable disease.
CONCLUSIONS: The results demonstrate an association between EBV reactivation and disease activity in MS patients over time, and suggest that EBV might play an indirect role in MS as an activator of the underlying disease process.
This article has been cited by other articles:
|
|
 |
|
  J. D. Lunemann, I. Jelcic, S. Roberts, A. Lutterotti, B. Tackenberg, R. Martin, and C. Munz EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-{gamma} and IL-2 J. Exp. Med., August 4, 2008; 205(8): 1763 - 1773. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Jilek, M. Schluep, P. Meylan, F. Vingerhoets, L. Guignard, A. Monney, J. Kleeberg, G. Le Goff, G. Pantaleo, and R. A. Du Pasquier Strong EBV-specific CD8+ T-cell response in patients with early multiple sclerosis Brain, July 1, 2008; 131(7): 1712 - 1721. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Zaadstra, A. Chorus, S. van Buuren, H. Kalsbeek, and J. van Noort Selective association of multiple sclerosis with infectious mononucleosis Multiple Sclerosis, April 1, 2008; 14(3): 307 - 313. [Abstract] [PDF]
|
|
|
|
 |
|
 J. D. Lunemann, T. Kamradt, R. Martin, and C. Munz Epstein-Barr Virus: Environmental Trigger of Multiple Sclerosis? J. Virol., July 1, 2007; 81(13): 6777 - 6784. [Full Text] [PDF]
|
|
|
|
 |
|
 T. R. Nielsen, K. Rostgaard, N. M. Nielsen, N. Koch-Henriksen, S. Haahr, P. S. Sorensen, and H. Hjalgrim Multiple Sclerosis After Infectious Mononucleosis Arch Neurol, January 1, 2007; 64(1): 72 - 75. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Lunemann, N. Edwards, P. A. Muraro, S. Hayashi, J. I. Cohen, C. Munz, and R. Martin Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis Brain, June 1, 2006; 129(6): 1493 - 1506. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.H. Hawkes Are multiple sclerosis patients risk-takers? QJM, December 1, 2005; 98(12): 895 - 911. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D Buljevac, G J J van Doornum, H Z Flach, J Groen, A D M E Osterhaus, W Hop, P A van Doorn, F G A van der Meche, and R Q Hintzen Epstein-Barr virus and disease activity in multiple sclerosis J. Neurol. Neurosurg. Psychiatry, October 1, 2005; 76(10): 1377 - 1381. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J E Friedman, J B Zabriskie, C Plank, D Ablashi, J Whitman, B Shahan, R Edgell, M Shieh, O Rapalino, R Zimmerman, et al. A randomized clinical trial of valacyclovir in multiple sclerosis Multiple Sclerosis, June 1, 2005; 11(3): 286 - 295. [Abstract] [PDF]
|
|
|
|
 |
|
 M. J Goldacre, C. J Wotton, V. Seagroatt, and D. Yeates Multiple sclerosis after infectious mononucleosis: record linkage study J. Epidemiol. Community Health, December 1, 2004; 58(12): 1032 - 1035. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Alvarez-Lafuente, V. De las Heras, M. Bartolome, J. J. Picazo, and R. Arroyo Relapsing-Remitting Multiple Sclerosis and Human Herpesvirus 6 Active Infection Arch Neurol, October 1, 2004; 61(10): 1523 - 1527. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C Contini, R Cultrera, S Seraceni, M Castellazzi, E Granieri, and E Fainardi Cerebrospinal fluid molecular demonstration of Chlamydia pneumoniae DNA is associated to clinical and brain magnetic resonance imaging activity in a subset of patients with relapsing-remitting multiple sclerosis Multiple Sclerosis, August 1, 2004; 10(4): 360 - 369. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Maurmann, L. Fricke, H.-J. Wagner, P. Schlenke, H. Hennig, J. Steinhoff, and W. J. Jabs Molecular Parameters for Precise Diagnosis of Asymptomatic Epstein-Barr Virus Reactivation in Healthy Carriers J. Clin. Microbiol., December 1, 2003; 41(12): 5419 - 5428. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L M. Grimaldi, A Pincherle, F Martinelli-Boneschi, M Filippi, F Patti, A Reggio, D Franciotta, L Allegra, G Comi, and F Blasi An MRI study of Chlamydia pneumoniae infection in Italian multiple sclerosis patients Multiple Sclerosis, October 1, 2003; 9(5): 467 - 471. [Abstract] [PDF]
|
|
|
|
 |
|
 P. Villoslada, C. Juste, M. Tintore, V. Llorenc, G. Codina, P. Pozo-Rosich, and X. Montalban The immune response against herpesvirus is more prominent in the early stages of MS Neurology, June 24, 2003; 60(12): 1944 - 1948. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C H Hawkes Is multiple sclerosis a sexually transmitted infection? J. Neurol. Neurosurg. Psychiatry, October 1, 2002; 73(4): 439 - 443. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J Hong, M V Tejada-Simon, V M Rivera, Y C. Zang, and J Z Zhang Anti-viral properties of interferon beta treatment in patients with multiple sclerosis Multiple Sclerosis, June 1, 2002; 8(3): 237 - 242. [Abstract] [PDF]
|
|
|
|
|
|
M. V. Tejada-Simon, Y. C. Q. Zang, J. Hong, V. M. Rivera, J. M. Killian, and J. Z. Zhang Detection of Viral DNA and Immune Responses to the Human Herpesvirus 6 101-Kilodalton Virion Protein in Patients with Multiple Sclerosis and in Controls J. Virol., May 13, 2002; 76(12): 6147 - 6154. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Rossig, C. M. Bollard, J. G. Nuchtern, C. M. Rooney, and M. K. Brenner Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy Blood, March 15, 2002; 99(6): 2009 - 2016. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-J. Gan, B. I. Razzouk, T. Su, and J. W. Sixbey A Defective, Rearranged Epstein-Barr Virus Genome in EBER-Negative and EBER-Positive Hodgkin's Disease Am. J. Pathol., March 1, 2002; 160(3): 781 - 786. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. D. Goodman and D. H. Miller Infections and MS: Clinical trials move to center stage Neurology, January 8, 2002; 58(1): 7 - 8. [Full Text] [PDF]
|
|
|
|
|
|
E. Bech, J. Lycke, P. Gadeberg, H.J. Hansen, C. Malmestrom, O. Andersen, T. Christensen, S. Ekholm, S. Haahr, P. Hollsberg, et al. A randomized, double-blind, placebo-controlled MRI study of anti-herpes virus therapy in MS Neurology, January 8, 2002; 58(1): 31 - 36. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ascherio, K. L. Munger, E. T. Lennette, D. Spiegelman, M. A. Hernan, M. J. Olek, S. E. Hankinson, and D. J. Hunter Epstein-Barr Virus Antibodies and Risk of Multiple Sclerosis: A Prospective Study JAMA, December 26, 2001; 286(24): 3083 - 3088. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. J. Jabs, H. Hennig, M. Kittel, K. Pethig, F. Smets, P. Bucsky, H. Kirchner, and H. J. Wagner Normalized Quantification by Real-Time PCR of Epstein-Barr Virus Load in Patients at Risk for Posttransplant Lymphoproliferative Disorders J. Clin. Microbiol., February 1, 2001; 39(2): 564 - 569. [Abstract] [Full Text]
|
|
|
|
|
|
D Krametter, G Niederwieser, A Berghold, G Birnbaum, S Strasser-Fuchs, H-P Hartung, and J J Archelos Chlamydia pneumoniae in multiple sclerosis: humoral immune responses in serum and cerebrospinal fluid and correlation with disease activity marker Multiple Sclerosis, February 1, 2001; 7(1): 13 - 18. [Abstract] [PDF]
|
|
|
|
|
|
A. F. Embry, R. A. Marrie, C. Wolfson, M. C. J. M. Sturkenboom, O. Gout, O. Heinzlef, E. Roullet, and L. Abenhaim Multiple sclerosis and antecedent infections: A case-control study Neurology, January 23, 2001; 56(2): 282 - 283. [Full Text] [PDF]
|
|
|
|
 |
|
 Are Epstein-Barr Virus Infection and Autoimmunity Linked in MS? Journal Watch Neurology, September 20, 2000; 2000(920): 2 - 2. [Full Text]
|
|
|
|
|
|
S. F. Hunter and D. A. Hafler Ubiquitous pathogens: Links between infection and autoimmunity in MS? Neurology, July 25, 2000; 55(2): 164 - 165. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
